Study details
Enrolling now
AGN-193408 SR Trial
AbbVie
NCT IDNCT04499248ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
96
Study length
about 8.3 years
Ages
18+
Locations
42 sites in AZ, CA, CT +18
About this study
Researchers are testing AGN-193408 SR in people with open-angle glaucoma or ocular hypertension. The trial will evaluate the safety and effectiveness of this treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Lumigan
- 2.Lumigan Vehicle
- 3.Sham Administration
- +1 more
PhasePhase 1/Phase 2
Primary goalChange from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study Eye
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study Eye, Number of participants experiencing treatment emergent adverse events
Body systems
Cardiology / Heart